Browsing by Author "Saloni Mangal"

Now showing 1 - 4 of 4

Advancements of Glucose Monitoring Biosensor: Current State, Generations of Technological Progress and Innovation Dynamics
(Bentham Science Publishers, 2025) Arpita Dua; Abhijit Debnath; Kunal Kumar; Rupa Mazumder; Avijit Mazumder; Rajesh Kumar Singh; Saloni Mangal; Jahanvi Sanchitra; Fahad Khan; Soumya Tripathi; Sukriti Vishwas; Hema Chaudhary; Parul Sharma; Shikha Srivastava
Glucose monitoring is essential for managing diabetes, and continuous glucose monitoring biosensors can offer real-time monitoring with little invasiveness. However, challenges remain in improving sensor accuracy, selectivity, and overall performance. This article aims to review current trends and recent advancements in glucose-monitoring biosensors while evaluating their benefits and limitations for diabetes monitoring. An analysis of current literature on transdermal glucose sensors was conducted, focusing on detection techniques, novel nanomaterials, and integrated sensor systems. Recent research has led to advancements in electrochemical, optical, electromagnetic, and sonochemical sensors for transdermal glucose detection. The use of novel nanomaterials and integrated sensor designs has improved sensitivity, selectivity, and accuracy. However, issues like calibration requirements, motion artifacts, and skin irritation persist. Transdermal glucose sensors show promise for non-invasive, convenient diabetes monitoring but require further enhancements to address limitations in accuracy, reliability, and biocompatibility. Continued research and innovation focusing on sensor materials, designs, and surface chemistry is needed to optimize biosensor performance and utility. The study offers a comprehensive analysis of the present status of technological advancement and highlights areas that need more research. © 2025 Bentham Science Publishers.
miRNA-Targeted Vaccines: A Promising Approach for Viral Attenuation and Immunogenicity Enhancement
(Bentham Science Publishers, 2025) Abhijit Debnath; Rupa Mazumder; Avijit Mazumder; Soumya Tripathi; Arpita Dua; Rajesh Kumar Singh; Saloni Mangal; Jahanvi Sanchitra; Pratibha Pandey; Biplab Pal; Hema Chaudhary; Parul Sharma; Shikha Srivastava
MicroRNAs (miRNAs) have emerged as a significant tool in the realm of vaccinology, offering novel approaches to vaccine development. This study investigates the potential of miRNAs in the development of advanced vaccines, with an emphasis on how they regulate immune response and control viral replication. We go over the molecular features of miRNAs, such as their capacity to direct post-transcriptional regulation toward mRNAs, hence regulating the expression of genes in diverse tissues and cells. This property is harnessed to develop live attenuated vaccines that are tissue-specific, enhancing safety and immunogenicity. The review highlights recent advancements in using miRNA-targeted vaccines against viruses like influenza, poliovirus, and tick-borne encephalitis virus, demonstrating their attenuated replication in specific tissues while retaining immunogenicity. We also explored the function of miRNAs in the biology of cancer, highlighting their potential to develop cancer vaccines through targeting miRNAs that are overexpressed in tumor cells. The difficulties in developing miRNA vaccines are also covered in this work, including delivery, stability, off-target effects, and the requirement for individualized cancer treatment plans. We wrap off by discussing the potential of miRNA vaccines and highlighting how they will influence the development of vaccination techniques for cancer and infectious diseases in the future. © 2025 Bentham Science Publishers.
Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes
(Taylor and Francis Ltd., 2024) Saloni Mangal; Abhijit Debnath; Rupa Mazumder; Avijit Mazumder; Rajesh Kumar Singh; Jahanvi Sanchitra; S.K. Asif Jan; Pratibha Pandey; Bimlesh Kumar; Anil Kumar Singh
Lung cancer is the leading cause of cancer-related deaths globally, accounting for 1.8 million fatalities in 2020. Genetic mutations, chromosomal abnormalities, transcription factors, mutations in tumor suppressor genes, and mutations in oncogenes have all been associated with an increased risk of LC development. Heterogeneity of the disease, resistance to chemotherapy, and side effects such as nausea and vomiting, fatigue, anemia, neuropathy, hair loss, and skin and nail changes are associated with conventional therapeutics such as chemotherapy, radiation therapy, and targeted therapy. Thus, the treatment of the disease urgently requires the discovery of novel therapeutic approaches. This review identifies and discusses key molecular and genetic targets for LC therapy, highlighting recent advancements and potential clinical applications. Our efforts encompass all biological targets and aim to increase our understanding of these processes to better comprehend the disease's molecular mechanisms and develop new drugs and more effective LC treatments. © 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Quest for discovering novel CDK12 inhibitor
(Taylor and Francis Ltd., 2025) Abhijit Debnath; Rajesh Kumar Singh; Rupa Mazumder; Avijit Mazumder; Shikha Srivastava; Hema Chaudhary; Saloni Mangal; Jahanvi Sanchitra; Pankaj Kumar Tyagi; S. K. Singh; Anil Kumar Singh
CDK12 is essential for cellular processes like RNA processing, transcription, and cell cycle regulation, inhibiting cancer cell growth and facilitating macrophage invasion. CDK12 is a significant oncogenic factor in various cancers, including HER2-positive breast cancer, Anaplastic thyroid carcinoma, Hepatocellular carcinoma, prostate cancer, and Ewing sarcoma. It is also regarded as a potential biomarker, emphasizing its broader significance in oncology. Targeting CDK12 offers a promising strategy to develop therapy. Various monoclonal antibodies have drawn wide attention, but they are expensive compared to small-molecule inhibitors, limiting their accessibility and affordability for patients. Consequently, this research aims to identify effective CDK12 inhibitors using comprehensive high-throughput virtual screening. RASPD protocol has been employed to screen three different databases against the target followed by drug-likeness, molecular docking, ADME, toxicity, Consensus molecular docking, MD Simulation, and in-vitro studies MTT assay. The research conducted yielded one compound ZINC11784547 has demonstrated robust binding affinity, favorable ADME features, less toxicity, remarkable stability, and cytotoxic effect. The identified compound holds promise for promoting cancer cell death through CDK12 inhibition. © 2024 Informa UK Limited, trading as Taylor & Francis Group.